Targeted c-Myc Inhibition and Systemic Temozolomide Therapy Extend Survival in Glioblastoma Xenografts
-
Published:2023-06-14
Issue:6
Volume:10
Page:718
-
ISSN:2306-5354
-
Container-title:Bioengineering
-
language:en
-
Short-container-title:Bioengineering
Author:
Dhungel Laxmi1, Harris Cayla1, Romine Lauren1ORCID, Sarkaria Jan2, Raucher Drazen1ORCID
Affiliation:
1. Department of Cell and Molecular Biology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA 2. Division of Radiation Oncology, Mayo Clinic and Foundation, 200 First Street, SW, Rochester, MN 55905, USA
Abstract
Glioblastoma is a highly aggressive disease with poor patient outcomes despite current treatment options, which consist of surgery, radiation, and chemotherapy. However, these strategies present challenges such as resistance development, damage to healthy tissue, and complications due to the blood–brain barrier. There is therefore a critical need for new treatment modalities that can selectively target tumor cells, minimize resistance development, and improve patient survival. Temozolomide is the current standard chemotherapeutic agent for glioblastoma, yet its use is hindered by drug resistance and severe side effects. Combination therapy using multiple drugs acting synergistically to kill cancer cells and with multiple targets can provide increased efficacy at lower drug concentrations and reduce side effects. In our previous work, we designed a therapeutic peptide (Bac-ELP1-H1) targeting the c-myc oncogene and demonstrated its ability to reduce tumor size, delay neurological deficits, and improve survival in a rat glioblastoma model. In this study, we expanded our research to the U87 glioblastoma cell line and investigated the efficacy of Bac-ELP1-H1/hyperthermia treatment, as well as the combination treatment of temozolomide and Bac-ELP1-H1, in suppressing tumor growth and extending survival in athymic mice. Our experiments revealed that the combination treatment of Bac-ELP1-H1 and temozolomide acted synergistically to enhance survival in mice and was more effective in reducing tumor progression than the single components. Additionally, our study demonstrated the effectiveness of hyperthermia in facilitating the accumulation of the Bac-ELP1-H1 protein at the tumor site. Our findings suggest that the combination of targeted c-myc inhibitory biopolymer with systemic temozolomide therapy may represent a promising alternative treatment option for glioblastoma patients.
Funder
National Cancer Institute/NIH
Reference38 articles.
1. Emerging therapies for glioblastoma: Current state and future directions;Rong;J. Exp. Clin. Cancer Res.,2022 2. Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets;Taylor;Front. Oncol.,2019 3. Cruz, J.V.R., Batista, C., Afonso, B.H., Alexandre-Moreira, M.S., Dubois, L.G., Pontes, B., Moura Neto, V., and Mendes, F.A. (2022). Obstacles to Glioblastoma Treatment Two Decades after Temozolomide. Cancers, 14. 4. Bidwell, G.L., Perkins, E., Hughes, J., Khan, M., James, J.R., and Raucher, D. (2013). Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model. PLoS ONE, 8. 5. Expert opinion on translational research for advanced glioblastoma treatment;Cui;Cancer Biol. Med.,2023
|
|